Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823913 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2EGLN3TSHR | |
| SCHEMBL27134481 | 0.71 | EGLN3 (0.48) | ALDH1A1MAPTSMN1; SMN2EGLN3TSHR | |
| SCHEMBL27134470 | 0.68 | EGLN3 (0.52) | ALDH1A1MAPTSMN1; SMN2EGLN3TSHR | |
| SCHEMBL23179030 | 0.67 | ALDH1A1 (0.40) | ALDH1A1MAPTSMN1; SMN2TSHRMEN1 | |
| SCHEMBL13017117 | 0.62 | EGLN3 (0.44) | ALDH1A1MAPTSMN1; SMN2EGLN3TSHR | |
| SCHEMBL10721461 | 0.61 | EGLN3 (0.47) | ALDH1A1MAPTSMN1; SMN2EGLN3MEN1 | |
| SCHEMBL824045 | 0.59 | — | — | |
| SCHEMBL3371124 | 0.59 | EGLN3 (0.44) | ALDH1A1MAPTSMN1; SMN2EGLN3MEN1 | |
| SCHEMBL1161082 | 0.59 | ALDH1A1 (0.51) | ALDH1A1MAPTSMN1; SMN2EGLN3TSHR | |
| SCHEMBL27237561 | 0.59 | EGLN3 (0.48) | ALDH1A1MAPTSMN1; SMN2EGLN3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | ALDH1A1 1035/4885MAPT 3394/4885SMN1; SMN2 2852/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | ALDH1A1 1035/4885MAPT 3394/4885SMN1; SMN2 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.